Accelerate the adoption of your diagnostic.
Speak to our expertsIllustration: a results monitor showing a rising bar-and-line chart, with a sample vial feeding into it and a scatter of data points behind.
Trusted by
The challenge
Diagnostic innovations inform roughly 60–70% of clinical decisions, while receiving only 2–5% of healthcare spending.1
In 2026, 67% of diagnostics executives identify reimbursement and market access as the decisive factor in growth.2
Many labs in the US face reimbursement cuts of up to 15% each year, greatly reducing payment levels for common tests.3
What we do
We turn promising diagnostics into adopted ones by helping our clients prove clinical value and secure reimbursement.
Portfolio prioritisation
Identify the next innovation in diagnostics
Specific offerings
- Unmet need mapping
- Clinical utility assessment of biomarkers
- Pharma pipeline analysis/matching
- Key opinion leader (KOL) advisory panels
Evidence
Demonstrate the clinical and economic value of your diagnostic
Specific offerings
- Evidence strategy/gap analysis
- Clinical study design (registrational and non-registrational)
- Real world evidence
- Health economics evaluations
- Evidence dissemination
Market access
Get approved and reimbursed in priority markets
Specific offerings
- Clinical pathway and guideline mapping
- Regulatory strategy and submission
- Reimbursement strategy
- HCP/payer engagement
Why Prova Health
Proven track record with the world's leading diagnostics companies
From prioritising biomarker candidates to defining reimbursement pathways, we've supported diagnostics innovation at every stage of the journey.
World-leading experts in diagnostics and evidence generation
Deep experience across IVDs, companion/standalone diagnostics, and AI-enabled diagnostics. From early portfolio decisions through to reimbursement and adoption.
Global clinical expert network
600+ healthcare insiders from 40+ countries in the proprietary Prova Health Network. 10× faster access to clinicians and experts to validate unmet need, clinical utility, and evidence strategy.
Case studies
View all case studiesPrioritising the next generation of neurology diagnostics through rigorous assessment of biomarker candidates
Evaluated 280+ biomarker candidates across four neurological conditions: multiple sclerosis (MS), Alzheimer’s Disease AD, Parkinson’s Disease (PD), and traumatic brain injury (TBI). Identified 30+ promising biomarkers to be prioritised for further development
Read the case study: Prioritising the next generation of neurology diagnostics through rigorous assessment of biomarker candidatesDefining the value proposition, mapping reimbursement pathways, and identifying relevant CPT codes for a top-10 diagnostics company's clinical algorithms
To quickly understand what commercialisation pathways existed for clinical algorithms in the US.
Read more: Defining the value proposition, mapping reimbursement pathways, and identifying relevant CPT codes for a top-10 diagnostics company's clinical algorithmsHelping Wellcome Leap - a world-leading philanthropic organisation - to prioritise investment in 12 new diagnostics aiming to cut stillbirth rates by half
Evaluated 12 technologies against criteria for success in the US, UK, Uganda, and India. In Utero received $100m in additional funding to reduce global stillbirths in line with our recommendations
Read more: Helping Wellcome Leap - a world-leading philanthropic organisation - to prioritise investment in 12 new diagnostics aiming to cut stillbirth rates by half
Frequently asked questions
Prova Health is headquartered in the UK and has an office in the US. A large proportion of our client base is in Switzerland. However, our work is truly global. We have also worked on projects in Germany, France, Spain, Italy, Canada, Brazil, Saudi Arabia, Japan and Australia (among many others).
In both diagnostics and digital health/AI our focus is on accelerating the adoption of innovation. The fact that we work across both innovation types is an added value for our clients. Digital health innovators benefit from our deep understanding of diagnostics as they consider go-to-market strategies and partnerships. Diagnostics companies benefit from our digital health expertise as they seek innovative ways to drive adoption of their innovations.
We work with diagnostics companies of all sizes - from early-stage biomarker developers to top-10 global diagnostics companies - across IVDs, companion diagnostics, standalone diagnostics, imaging, and AI-enabled diagnostics.
Yes. Our portfolio prioritisation work helps diagnostics companies assess unmet clinical need, competitive landscape, and reimbursement feasibility across candidate tests, so that investment goes toward the innovations most likely to succeed. We've done this for individual companies and for philanthropic funders prioritising across dozens of candidate diagnostics.
Yes. We work with both diagnostics companies and their pharma partners to align evidence generation and regulatory strategy for companion diagnostics (CDx) and standalone diagnostics (SDx), drawing on our experience across both sectors.
Evidence services focus on generating the clinical and economic data that prove your diagnostic works and adds value (study design, real-world evidence, health economics). Market access services focus on turning that evidence into approval and reimbursement, and involves mapping clinical guidelines, identifying CPT codes, and engaging payers and HCPs.